Synthesis, bioevaluation and docking studies of new imidamide derivatives  as nitric oxide synthase inhibitors. by Arias, Fabio et al.
Bioorg. Med. Chem. 44 (2021) 116294
Available online 28 June 2021
0968-0896/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Synthesis, bioevaluation and docking studies of new imidamide derivatives 
as nitric oxide synthase inhibitors 
Fabio Arias a, Francisco Franco-Montalban a, Miguel Romero b,c,d,e, M. Dora Carrión a,*,1, 
M. Encarnación Camacho a,*,1 
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Nitric Oxide Synthase 
Synthesis 
A B S T R A C T   
In search of new Nitric Oxide Synthase (NOS) inhibitor agents, two isosteric series of derivatives with an imi-
damide scaffold (one of them with a hydroxyl group and the other with a carbonyl one) were synthesized and 
evaluated on inducible (iNOS) and neuronal (nNOS) isoforms. These compounds have been designed by 
combining a kynurenamine framework with an amidine moiety in order to improve selectivity for the inducible 
isoform. In general, the in vitro inhibitory assays exhibited better inhibition values on the iNOS isoform, being the 
N-(3-(2-amino-5-methoxyphenyl)-3-hydroxypropyl)-4-(trifluoromethyl)benzimidamide 4i the most active in-
hibitor with the highest iNOS selectivity, without inhibiting eNOS. Docking studies on the two most active 
compounds suggest a different binding mode on both isozymes, supporting the experimentally observed selec-
tivity towards the inducible isoform. Physicochemical in silico studies suggest that these compounds possess good 
drug-likeness properties.   
1. Introduction 
Nitric oxide (NO) is a heterodiatomic molecule with an unpaired 
electron which behaves as a free radical. Its small size, lack of charge, 
and high solubility, allow NO to freely diffuse through any cellular 
membrane in the organism.1 
NO is produced by the Nitric Oxide Synthase (NOS) during the 
transformation of L-arginine to L-Citrulline, consuming NADPH and O2. 
There are three different isoforms named according to the place where 
they can be found: neurons (nNOS), endothelium (eNOS) or induced by 
the immune system (iNOS), being involved, respectively, in neuro-
transmission, smooth tissue relaxation and the immune response.2 
Dysregulated NO levels are implicated in different disorders.3 For 
example, the overproduction of NO by nNOS has been proven as a 
common factor in a wide range of neurological deficits such as Alz-
heimer’s, Huntington’s, Parkinson’s, and amyotrophic lateral sclerosis.4 
Whereas, iNOS overexpression highly increases the NO levels, which 
later reacts with superoxide radical to produce reactive nitrogen species 
(RNSs). These RNSs take part in several inflammatory and/or oxidative 
stress pathways, contributing in the development of various patholog-
ical conditions such as Parkinson’s disease, Alzheimer’s disease,5,6 
sepsis, heart failure,7 multiple sclerosis,8 rheumatoid arthritis,9 diabetes 
mellitus,10 inflammatory bowel disease11 and acute lung injury.12 
Nowadays, the involvement of NO in cancer is well known, specially, 
how the iNOS activity affects tumour progression.13,14 Thus, the in-
crease in iNOS expression has been found in different cancer types, such 
as breast,15 colon,16 pancreatic17 and lung18 cancers, as well as in head 
and neck squamous carcinoma19 glioblastoma,20,21 and melanoma.22 
The main role of eNOS isoform is producing NO in order to relax 
vasculature, inhibit platelet and white cell adhesion, prevent smooth 
muscle cell replication, promote angiogenesis, and control the expres-
sion of vascular endothelium growth factor (VEGF).23,24 In this sense, 
eNOS inhibition can lead to severe hypertension or other cardiovascular 
disorders. 
Currently, the exploration of potent and selective NOS inhibitors 
could signify a step forward in future therapies for pathologies involving 
* Corresponding authors. 
E-mail addresses: dcarrion@ugr.es (M.D. Carrión), ecamacho@ugr.es (M.E. Camacho).   
1 These authors contributed equally. 
Contents lists available at ScienceDirect 
Bioorganic & Medicinal Chemistry 
journal homepage: www.elsevier.com/locate/bmc 
https://doi.org/10.1016/j.bmc.2021.116294 
Received 11 May 2021; Received in revised form 18 June 2021; Accepted 19 June 2021   
Bioorganic & Medicinal Chemistry 44 (2021) 116294
2
NO overproduction. Thus, the development of selective nNOS inhibitors 
would be important to better understand the role of NO in the central 
nervous system and to deepen in the research of neurodegenerative 
disorders.25 Besides, the investigation of selective iNOS inhibitors could 
be crucial for the research of new treatments for diseases where the 
immune and inflammatory response of the organism is involved, such as 
septic shock or rheumatoid artritis.26 
Most compounds initially investigated as NOS inhibitors were 
designed mimicking the L-arginine structure, such as L-NAME (L-NG- 
nitroarginine methyl ester). These molecules cannot be used clinically, 
since they are able to inhibit eNOS and, therefore, induce hyperten-
sion.27 In order to find selective NOS inhibitors, we have already 
investigated different kynurenamine derivatives 1 (Fig. 1).28 Afterward 
the substituted acyl group in compounds 1 was modified to obtain de-
rivatives 229 with a urea or thiourea moiety finding interesting mole-
cules, such as the iNOS/nNOS selective oxopropyl-urea 2a (R1 = Cl, R2 
= Et, X  = O; IC50 = 100 μM in iNOS; IC50 > 1000 μM in nNOS). Then, we 
have replaced the carbonyl group by a hydroxyl one, obtaining prom-
ising hydroxyproyl-ureas and thioureas 3,30 as derivative 3a (R1 = OMe, 
R2 = Me, X  = S; IC50 = 180 μM in iNOS; IC50 = 130 μM in nNOS). In the 
last years different aliphatic, aromatic and cyclic amidines have been 
studied as competitive iNOS inhibitors.27 Thereby, in this paper we have 
investigated different derivatives with an amidine scaffold, and set a 
synthetic procedure to join two structural components, a kynurenamine 
skeleton with an imidamide residue. In vitro inhibition assays on iNOS 
and nNOS have been done on all synthesized compounds and the best 
performing molecules selected for the determination of its IC50 values. 
Docking studies have also been carried out to account for the NOS iso-
form selectivity observed. 
2. Results and discussion 
2.1. Chemistry 
Scheme 1 depicts the synthetic strategy adopted for the preparation 
of target compounds 4a-i and 5a-h. 5-Methoxy-2-nitrobenzaldehyde 6c 
(synthesized by methylation with MeI and K2CO3),31 along with the 
commercial 2-nitrobenzaldehyde 6a and 5-chloro-2-nitrobenzaldehyde 
6b, were converted into the 3-(5-substituted-2-nitrophenyl)-3-hydrox-
ypropanenitriles 7a-c by treatment with n-BuLi and CH3CN in dry THF. 
The nitrile group of these derivatives was reduced selectively with BH3/ 
THF to the primary amines 8a-c.30 For the next step, it was necessary to 
synthesize the benzyl-benzimidothioates 9b-d, starting from benzyl 
bromide and the corresponding benzothioamides (Scheme 2).32 
The reaction between the amine group of the distinct 3-amino-1-(2- 
nitro-5-substitutedphenyl)-propan-1-ols 8a-c and the different imidates 
9a-d, which includes the commercially available ethyl acetimidate 9a, 
generated the imidamide function present in the nine nitro-
phenylimidamide intermediates 10a-I, which were turned into the final 
N-(3-(2-amino-5-substitutedphenyl)-3-hydroxypropyl)imidamides 4a-i 
using Fe/FeSO4 as reducing agent. In addition, the hydroxyl group of the 
diverse imidamides 10a-h was oxidized to a carbonyl one with Jones 
reagent, to give the corresponding ketones 11a-h. Finally, the nitro 
group of these intermediates were reduced to afford the final N-(3-(2- 
amino-5-substitutedphenyl)-3-oxopropyl)imidamides 5a-h, as 
described for 4a-i. 
2.2. Biological activity evaluation 
2.2.1. iNOS and nNOS inhibition 
In order to elucidate the biological activity of the novel compounds 
as iNOS and nNOS inhibitors, in vitro assays employing human recom-
binant isoforms have been carried out. The data presented in Table 1 
show the results of the preliminary inhibition screening for the final 
imidamides 4a-i and 5a-h. The tests were conducted at a terminal 
concentration of 1 mM in both isoforms. The range of values obtained 
oscillated between 16.22% and 99.61% in iNOS and between 7.18% and 
89.16% in nNOS. Based on this preliminary evaluation, the new de-
rivatives exhibited better inhibition values on the inducible isoform than 
on the neuronal one. In this sense, twelve molecules showed a 
Fig. 1. Graphic overview of new imidamides described by our research group.  
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percentage of inhibition greater than 50% on iNOS while eight 
compounds inhibited nNOS also with percentages of inhibition greater 
than 50%. In general, molecules with a hydroxypropyl group (de-
rivatives with general structure 4) exhibited higher percentages of iNOS 
inhibition, while those with a carbonyl rest (compounds type 5) better 
inhibited the neuronal isoform. 
Regarding the iNOS inhibition values, it can be seen that, in general, 
molecules with an electron-donating substituent in R1 (OMe) show the 
highest inhibition rates versus this isozyme (4g-i, 5f-h), except for 5e, 
which has a high percentage of inhibition on iNOS and contains an 
electron-withdrawing group (R1 = Cl). 
With respect to neuronal isoform, derivatives 5f-h (R1 = OMe) 
behave as good nNOS inhibitors, along with 5a (R1 = H). 
Despite presenting such a large range of percentages, iNOS selec-
tivity prevails in most of these compounds, with the exception of the last 
members of this family 5f-h, where a greater inhibition in nNOS is 
observed. 
Among all candidates, the best performing in terms of percentage of 
inhibition were selected for the evaluation of their IC50 values on the 
inducible isoform and on the neuronal one (see Table 2). The IC50 values 
observed for iNOS range between 20.0 and 59.7 µM. The most active 
iNOS inhibitors of all tested compounds are the 3-hydroxypropyl de-
rivatives with a methoxy group in R1, 4i (R2 = p-CF3Ph, IC50 = 20.0 µM) 
and 4g (R2 = Ph, IC50 = 22.5 µM), also presenting selectivity toward 
nNOS. In addition, the oxopropyl derivative 5e (R1 = Cl, R2 = Me) 
Scheme 1. Synthetic route of novel imidamides 4a-i and 5a-h. Reagents and conditions: a) CH3CN, BuLi, THF, − 78 ◦C, then RT; b) BH3-THF, 0 ◦C, then 4 h RT; c) 
MeOH 0 ◦C, then 15 h RT; d) CrO3, CH3COCH3, H2SO4, DCM 0 ◦C, 10 min; e) Fe/FeSO4, H2O, 100 ◦C, 1.5 h. 
Scheme 2. Synthesis of benzimidothioates 9b-d. Reagents and conditions: (a) 
CHCl3, reflux 2 h. 
Table 1 
In vitro iNOS and nNOS inhibition (%) observed in the presence of 1 mM con-
centration of compounds 4a-i and 5a-h.  
Compound R1 R2 % iNOS inhibitiona % nNOS inhibitiona 
4a H Me 16.22 ± 1.89 28.26 ± 2.20 
4b H Ph 64.09 ± 2.63 23.19 ± 1.88 
4c H p-ClPh 73.17 ± 1.38 31.57 ± 0.82 
4d H p-CF3Ph 60.50 ± 2.33 36.45 ± 1.49 
4e Cl Me 49.11 ± 1.25 66.11 ± 1.17 
4f OMe Me 57.39 ± 1.42 19.01 ± 2.75 
4g OMe Ph 95.91 ± 0.27 7.18 ± 2.81 
4h OMe p-ClPh 81.02 ± 1.80 58.47 ± 0.69 
4i OMe p-CF3Ph 99.61 ± 0.55 12.50 ± 1.06 
5a H Me 22.25 ± 0.84 88.83 ± 0.45 
5b H Ph 35.63 ± 2.25 66.47 ± 1.02 
5c H p-ClPh 33.42 ± 2.48 37.43 ± 1.67 
5d H p-CF3Ph 68.61 ± 1.28 55.98 ± 0.23 
5e Cl Me 99.14 ± 0.69 19.88 ± 0.57 
5f OMe Me 97.59 ± 1.24 89.16 ± 0.61 
5g OMe Ph 94.73 ± 0.50 85.86 ± 1.62 
5h OMe p-ClPh 75.12 ± 1.46 86.44 ± 0.99 
2ab Cl Et 78.63 ± 1.34 9.86 ± 3.17 
3ab OMe Me 76.55 ± 0.33 80.55 ± 2.29  
a Values are the mean ± SEM of the percentage of iNOS and nNOS inhibition 
produced by 1 mM concentration of each compound. Each value is the mean of 
three experiments performed by triplicate using recombinant iNOS and nNOS 
enzymes. b2a29 and 3a30 were used as reference. 
Table 2 
IC50 values (μM) for the inhibition of iNOS and nNOS activities by the most 
potent imidamide derivatives 4g, 4i, 5a and 5e-g.  
Compound iNOSa nNOSa 
4g 22.5 >1000 
4i 20.0 >1000 
5a >1000 324.7 
5e 25.6 >1000 
5f 59.7 223.3 
5g 45.2 193.7 
2ab 100 >1000 
3ab 180 130  
a Data obtained by measuring the percentage of inhibition on at least six 
concentrations of each compound. 
b 2a29 and 3a30 were used as reference. 
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exhibited an iNOS inhibition value almost comparable to its previous 
isosters (IC50 = 25.6 µM), maintaining selectivity for this isoform. 
In nNOS, the IC50 values obtained are significantly higher than on 
iNOS, being the molecules with a carbonyl rest the best inhibitors, 
ranging from 193.7 µM in 5g to 324.7 µM for 5a, the latter being the 
compound presenting the best selectivity on nNOS. In this way, the 
replacement of the hydroxyl moiety for a carbonyl one decreases the 
iNOS potency and the selectivity versus nNOS. 
These two series of imidamide derivatives have been designed by 
isosteric replacement from the oxopropyl-ureas and tioureas of general 
structure 229 and the hydroxypropyl-ureas and thioureas 330, being the 
most active molecules in each series the oxopropylurea 2a (R1 = Cl, R2 
= Et, X = O; IC50 = 100 µM in iNOS and selectivity versus nNOS) and the 
hydroxypropyl-thiourea 3a (R1 = OMe, R2 = Me, X = S; IC50 = 180 µM 
versus iNOS and 130 µM in nNOS) (Table 2). In this regard, the amidine 
residue in imidamides 4 and 5 improve de iNOS inhibition values when 
compared to their previous isosters 3 and 2, in addition to the iNOS/ 
nNOS selectivity regarding the hydroxypropyl-thioureas. 
2.2.2. eNOS inhibition activity 
As indicated above, the undesirable side effects for NOS inhibitors 
derive from the alteration of the endothelial isoform. Hence, in order to 
prove that our most potent inhibitor, does not affect the cardiovascular 
system, a functional test with 4i was carried out. In this way, 
acetylcholine-induced endothelium-dependent relaxation has been 
studied using endothelium intact rat aortic rings. This classic cholinergic 
agonist activates eNOS by a calcium-dependent mechanism.33 The 
endothelium-dependent relaxation to acetylcholine was not affected by 
4i (Fig. 2), confirming the absence of eNOS inhibition of this compound, 
whereas the non-selective NOS inhibitor L-NAME almost abolished this 
response. 
2.2.3. Cell viability (cytitixicity determination) 
We investigated the cell viability activity of compounds 4g, 4i, 5e 
and 5g using HUVECs. The tested concentrations were within the range 
of IC50 values for the inhibition of iNOS activity by the most potent 
imidamide derivatives. We observed that these compounds had little 
toxicity, but not significant as compared with the control conditions, 
since only at higher concentration tested (500 µM) the cell viability is 
weakly (approximately 20%) reduced (Fig. 3). 
2.3. Molecular docking study 
Docking studies on human proteins iNOS and nNOS (pdb IDs 4CX7 
and 6AV2) were performed to shed some light on the binding mode of 
these imidamide derivatives, and to account for the selectivity differ-
ences observed experimentally on both enzymes. Compounds were 
selected for the docking analysis as they perform best on the inhibition 
assays. Before any calculations were made, redocking of the cognate 
ligands on crystal structures 4CX7 and 6AV2 were carried out to account 
for the validity of docking protocol. In both cases, the preferred poses for 
the cognate ligands matched those of the crystal structures (results not 
shown). Next, compounds 4g and 4i were docked on human iNOS (pdb 
4CX7) and nNOS (pdb 6AV2). Fig. 4a shows the preferred binding poses 
of both compounds on the catalytic active site of iNOS. 
4g displays its phenyl ring underneath the Fe atom of the heme group 
favoring a π–cation interaction (Fig. 4a). Its imidamide group is dis-
played toward the carboxylate residues of the heme group forming a H- 
bond. Similarly, 4i orients its p-CF3Ph moiety directly underneath the Fe 
atom of the heme group, and because of its bulkier p-trifluorophenyl 
imidamide group, is forced to display the imidamide group away from 
the catalytic site and toward the carboxylate residues of the heme group. 
Unlike 4g, 4i can establish a H-bond with Gln263 at the entrance of the 
catalytic pocket. As these poses show, the imidamide groups of 4g and 4i 
are not binding the catalytic residue Glu377 as expected, however it 
should be noted the disposition of the p-methoxyaniline ring. In both 
compounds the ring is displayed toward a catalytic pocket generated by 
Gln263, Tyr347, Arg388, Asp382 and Tyr373, H-bonding the important 
catalytic residues Arg388, Asp382 and Tyr373. 
These poses are of significance if we compare them with those 
adopted by NPA (Nω-propyl-L-arginine), and the natural substrate L- 
arginine, on the catalytic site of iNOS. Both compounds, 4g and 4i, show 
binding interactions with at least two of the catalytically important 
residues in the active site region.34 
As for the binding poses of 4g and 4i on the nNOS they are shown in 
Fig. 4b. Like the poses seen on iNOS, in the neuronal model both com-
pounds display their phenylimidamide moiety under the heme group, 
although with significant differences. 4i and 4g display its imidamide 
group toward Glu597 (Glu377 on iNOS) but no H-bonds are established 
with this residue. As for the p-methoxyaniline ring, and unlike the poses 
with the iNOS isozyme, both ligands display this moiety toward the 
carboxylic acids of the heme group, although only 4i can H-bond the 
4i4i
Fig. 2. Effect of compound 4i on eNOS activity. Acetylcholine-evoked relaxa-
tion in aortic rings with endothelium contracted with 1 μmol/L noradrenaline, 
after incubation with L-NAME (100 μM), 4i (20 μM), or its vehicle (DMSO, 1/ 
106) for 30 min. Data are expressed as mean ± SEM of n experiments. **P <
0.01 vs. rings incubated with vehicle. 
Fig. 3. Effect of compounds 4g, 4i, 5e and 5g on cell viability assessed by MTT 
reduction in HUVECs. Results were calculated as percentage of control (un-
treated cells) and data are presented as mean ± standard error of the mean 
(SEM) (n = 3 per group). 
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carboxylic moieties as well as the tetrahydrobiopterin (BH4) cofactor. 4g 
on the other hand, H-bond residue Asn574 (Asn354 on iNOS) at the 
entrance of the catalytic channel. 
Although both poses are similar in terms of orientations, the reduced 
number of binding interactions in nNOS, and the tendency to bind the 
catalytically important pocket generated by residues Gln263, Tyr347, 
Arg388, Asp382 and Tyr373 in iNOS, might explain the low selectivity 
of both compounds toward nNOS found on the IC50 assays. 
To account for the differences in orientation of 4g and 4i in both 
isozymes, the predicted binding poses are shown in Fig. 4c-d where the 
enzymes are represented as a Van der Waals surface. These pictures 
show the preference of the docked compounds to bid the region un-
derneath the BH4 cofactor and near the catalytic residues on iNOS, 
suggesting a higher selectivity toward this isozyme. 
2.4. In silico prediction of physicochemical parameters and ADME 
properties 
2.4.1. Physicochemical parameters 
After potency and selectivity, another key aspect in the design of 
drugs is optimizing the administration route. A good strategy for pre-
dicting the oral bioavailability of a drug is to check if the compound 
meets the Lipinski and Veber rules. Lipinski’s rules state that for a 
compound to be administered orally, it should meet at least three of the 
following conditions: (a) have a molecular weight below 500; (b) have 
an octanol–water partition coefficient below 5; (c) have no more than 5 
hydrogen bond donor atoms; and (d) have no more than 10 hydrogen 
bond acceptor atoms.35 Afterwards, Veber establishes additional rules 
for drug bioavailability: (a) the number of rotatable bonds must be less 
than 10, and (b) the polar surface area must be no greater than 140 Å2.36 
In this article the Lipinski and Veber rules have been calculated for the 
compounds with the most interesting biological activity (4g, 4i, 5e, 5f 
and 5g) using the free access website: https://www.molsoft.com/server 
s.html. These results are shown in Table 3. All compounds comply the 
Lipinski and Veber rules, so it could be predicted that they will present a 
high oral bioavailability. 
2.4.2. ADME properties 
The evaluation of the pharmacokinetic properties of absorption, 
distribution, metabolism and excretion are very important for devel-
oping a new therapeutic agent, to save time and costs. In order to 
calculate these properties in the most active compounds we have used 
the free access website: https://preadmet.bmdrc.kr/. These results are 
shown in Table 4. 
Human intestinal absorption is one of the most important parameters 
in drug discovery. It is considered high absorption: 70–100%, medium 
absorption: 20–70% and low absorption: 0–20%.37 These compounds 
have a high intestinal absorption which reinforces the theory that they 
could be good candidates for the design of oral drugs. Penetration 
through the blood–brain barrier can be advantageous if the drug exerts 
its effect on the central nervous system, but harmful if the drug acts only 
at the peripheral level. High penetration through the blood–brain bar-
rier is considered >2, medium absorption 2-0.1, and low absorption 
<0.1.37 The imidamide derivatives have shown moderate values of BBB 
penetration, in the case of the compounds 4g and 4i these values could 
be improved making a prodrug by the esterification of the hydroxyl 
group. 
Plasma proteins binding could influence the half-life of a drug, since 
the protein-bound portion could act as a deposit of the drug that will be 
released slowly. A high union is estimated: >90%, and a weak union: 
<90.37 According to theoretical calculations, the imidamide 4i is the 
compound that shows the highest binding to plasma proteins. 
CYP3A4 and CYP2C19 are cytochrome P450 enzymes responsible for 
drug metabolism, the inhibition of these proteins could cause an in-
crease in plasma levels and toxicity. The in silico calculations indicate 
that these compounds are not inhibitors of these cytochromes. 
A drug-like score is a value that indicates theoretically the similarity 
of a compound to a known therapeutic agent. A score of 1 shows that the 
compound is a good candidate to be a therapeutic agent.38 Derivatives 
4g and 4i present predicted values very close to 1, which is a good 
theoretical data in the development of new drugs. 
3. Conclusions 
Along this paper, the successful synthetic route for seventeen novel 
molecules has been described. In this process, two well-known struc-
tures in NOS inhibition: the imidamide core and kynurenamine skeleton 
have been fused, introducing at the same time, several moieties with 
different electronic characteristics. These modifications allowed us to 
study the way each one affected the activity. All final compounds were 
subjected to an inhibition screening on the neuronal and inducible NOS 
isoforms, selecting those with highest inhibition percentages for further 
Fig. 4. (a) Superposition of predicted binding poses of 4g (green) and 4i 
(yelow) in iNOS (pdb ID 4CX7, tan). Hydrogen bonds are represented by dashed 
purple lines. (b) Superposition of predicted binding poses of 4g (green) and 4i 
(yelow) in nNOS (pdb ID 6AV2, blue). Hydrogen bonds are represented by 
dashed purple lines. (c). Superposition of the predicted binding poses of 4g 
(green) and 4i (yelow) in iNOS depicted as a Van der Waals surface. Red 
(negative charge), blue (positive charge), white (neutral). Heme group and BH4 
cofactor are represented as tan sticks and hydrogen bonds as dashed purple 
lines. (d) Superposition of the predicted binding poses of 4g (green) and 4i 
(yelow) in nNOS depicted as a Van der Waals surface. Red (negative charge), 
blue (positive charge), white (neutral). Heme group and BH4 cofactor are 
represented as blue sticks and hydrogen bonds as dashed purple lines. 
Table 3 
Calculated Lipisnki and Veber parameters for compounds 4g, 4i, 5e, 5f and 5g.  
Comp. MW LogP HBD HBA nVs nRB MolPSA 
Lipinski* ≤500 ≤5 ≤5 ≤10  – – 
Veber** – – – – – ≤10 ≤140 
4g 299.16 1.65 5 3 0 7 72.40 Å2 
4i 367.15 2.71 5 3 0 8 72.40 Å2 
5e 239.08 1.49 4 2 0 5 72.40 Å2 
5f 235.13 0.84 4 3 0 6 70.08 Å2 
5g 297.15 2.16 4 3 0 7 69.49 Å2 
*Lipinski reference values; ** Veber reference values; MW, Molecular weight; 
LogP, lipophilicity (O/W); HBD, Number of hydrogen bond donors; HBA, 
Number of hydrogen bond acceptors; nVs, Number of Lipinski rule violations; 
nRB, Number of rotatable bonds; MolPSA, molecular polar surface area (PSA) 
(Å2). 
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analysis in form of IC50. The chosen ones were (4h, 4i, 5e-g) for iNOS, 
and (5a, 5f-g) for nNOS, showing better inhibition values in the 
inducible isoenzyme, being 4g (IC50 = 22.5 μM) and 4i (IC50 = 20.0 μM) 
the best inhibitors. Using in silico models these compounds have shown 
an interesting oral bioavailability. Data obtained from docking studies 
on 4g and 4i reveal that these derivatives show their p-methoxyaniline 
ring toward an important catalytic pocket on iNOS establishing H-bond 
interactions with three vital residues, Gln263, Tyr373 and Asp382, 
meanwhile on nNOS the same scaffold shifts toward Asn574 (Asn354 on 
iNOS) at the entrance of the catalytic channel which could explain their 
iNOS selectivity. Furthermore, the cell viability test proved the absence 
of cytotoxicity in the most potent inhibitors at their IC50 values. 
Regarding the pharmacological experiments with aortic rat tissue, we 
can conclude that 4i does not modify the relaxation associated to ACh 
making this compound an effective iNOS inhibitor. Moreover, this 
compound could be considered a new selective iNOS inhibitor for the 
development of new therapies for the treatment of inflammatory dis-
orders, such as septic shock or rheumatoid arthritis, among others. 
4. Experimental section 
4.1. Chemistry 
All starting materials, reagents and solvents, were commercially 
available. 1H NMR and 13C NMR spectra were obtained using Bruker 
Avance NEO spectrometers with Smart Probe BBFO equipped, operating 
at 400.57 MHz for 1H and 100.73 MHz for 13C, at 499.79 MHz for 1H and 
125.68 MHz for 13C, or 600.25 MHz for 1H and 150.95 MHz for 13C, in 
the deuterated solvents. Chemical shifts are reported in ppm (δ ppm) and 
are referenced to the residual solvent peak. HRMS was conducted on a 
Waters LCT Premier Mass Spectrometer. Melting points were deter-
mined on an electrothermal melting point apparatus and were 
uncorrected. 
General method for the synthesis of 3-(2-nitro-5-substitutedphenyl)3- 
hydroxypropanenitriles 7a-c. n-BuLi (1.6 M/hexane, 12.5 mL) was added 
to dry THF (20 mL) cooled to − 78 ◦C under argon; then, acetonitrile 
(1.572 mL) was added dropwise. The mixture was stirred at − 78 ◦C for 1 
h. Afterward, a solution of the corresponding 2-nitrobenzaldehydes 6a-c 
(10 mmol) in dry THF (10 mL) was added dropwise. The mixture was 
stirred again at − 78 ◦C for 30 min and then warmed to RT. The mixture 
reaction was quenched with cold water (25 mL) and concentrated under 
vacuum. The crude was extracted with EtOAc (3 × 30 mL) and the 
organic phase was washed with NaHCO3 saturated solution (15 mL) and 
brine (15 mL), dried over anhydrous Na2SO4, filtered and evaporated. 
The crude was purified by flash chromatography (EtOAc/hexane, 1: 4). 
3-(2-Nitrophenyl)3-hydroxypropanenitrile (7a).30 Yellow solid: mp: 
82–85 ◦C; 93% yield. 
3-(5-Chloro-2-nitrophenyl)3-hydroxypropanenitrile (7b).30 Yellow 
solid; mp: 63–43 ◦C; 75% yield. 
3-(5-Methoxy-2-nitrophenyl)3-hydroxypropanenitrile (7c).30 Yellow 
solid: mp: 88–90 ◦C; 86% yield. 
General method for the synthesis of 3-amino-1-(2-nitro-5- 
substitutedphenyl)-propan-1-ols 8a-c.30 A solution of 1 M BH3 (10 mL) in 
THF under argon was cooled to 0 ◦C and was added to the different 3-(2- 
nitro-5-substitutedphenyl)3-hydroxypropanenitriles 7a-c (2.0 mmol) 
dropwise. The mixture was stirred for 5 h at RT. Afterward, the reaction 
mixture was cooled to 0 ◦C and an ice-cold solution of 6 N HCl (8.5 mL) 
was added carefully. The THF was evaporated, and the aqueous phase 
was basified with 10 M NaOH to pH = 8–9 and extracted with EtOAc (3 
× 15 mL). The organic phase was washed with brine, dried over Na2SO4 
and evaporated. The crude was used for the next step without 
purification. 
General method for the synthesis of the benzyl-benzimidothioates 9b-d. 
Commercially available benzothioamides (benzothioamide, 4-chloro-
benzothioamide or 4-(trifluoromethyl)benzothioamide) (5 mmol) were 
dissolved in CHCl3 (15 mL); then, benzyl bromide (5.5 mmol, 634 µl) 
were added and the mixture was refluxed for 2 h. After cooling, the 
resulting white solid was filtered under vacuum. 
Benzylbenzimidothioate hydrobromide (9b).32 White solid; mp: 
194–196 ◦C; 94% yield. 
Benzyl 4-chlorobenzimidothioate hydrobromide (9c).39 White solid; 
mp: 182–184 ◦C; 90% yield. 
Benzyl 4-(trifluoromethyl)benzimidothioate hydrobromide (9d). White 
solid; mp: 147–145 ◦C; 79% yield. 1H NMR (400 MHz, DMSO d6): δ 
11.02 (sa, 1H), 8.08 (d, J = 7.7 Hz, 2H), 8.00 (d, J = 7.7 Hz, 2H), 7.53 (d, 
J = 7.0 Hz, 2H), 7.39 (m, 3H), 4.75 (s, 2H). 13C NMR (100 MHz, 
DMSO d6) δ 166.68, 137.32, 135.01, 132.72, 129.39, 128.41, 128.34, 
127.31, 125.26 (q, J = 3.4 Hz), 123.40 (q, J = 272.4 Hz), 41.58. HRMS 
(LSIMS): m/z calcd for C15H13NSF3: 296.0721 [M + H]+; found: 
296.0733. 
General method for the synthesis of N-(3-(2-nitro-5-substitutedphenyl)- 
3-hydroxypropyl)imidamides 10a-i. 3-Amino-1-(2-nitro-5-substituted-
phenyl)propan-1-ol derivatives 8a-c (2 mmol) were solved in MeOH 
(10 mL) and cooled to 0 ◦C; then, the different imidates 9a-d (3 mmol) 
were added. The mixture was stirred for 15 h at room temperature. 
Afterward, the reaction mixture was evaporated and was purified by 
flash chromatography (DCM: MeOH, 9: 1 saturating with NH4OH). 
N-(3-Hydroxy-3-(2-nitrophenyl)propyl)acetimidamide (10a). Orange 
oil; 88% yield. 1H NMR (400 MHz, CD3OD) δ 7.90 (dd, J = 7.5 Hz, J =
4.7 Hz, 2H), 7.71 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 5.24 (d, J 
= 9.2 Hz, 1H), 3.60–3.42 (m, 2H), 2.26 (s, 3H), 2.19–2.07 (m, 1H), 
1.95–1.84 (m, 1H). 13C NMR (100 MHz, CD3OD) δ 166.08, 148.74, 
141.51, 134.70, 129.40, 129.11, 125.22, 67.34, 40.75, 37.29, 19.08. 
HRMS (LSIMS): m/z calcd for C11H15N3O3: 238.1192 [M + H]+; found: 
238.1178. 
N-(3-Hydroxy-3-(2-nitrophenyl)propyl)benzimidamide (10b). Brown 
oil; 71% yield. 1H NMR (400 MHz, DMSO d6) δ 9.77 (sa, 1H), 9.48, 9.05 
(sa, 1H), 7.91 (dd, J = 8.3 Hz, J = 1.1 Hz, 1H), 7.87 (dd, J = 7.9 Hz, J’ =
1.3 Hz, 1H), 7.81–7.67 (m, 4H), 7.61 (t, J = 7.6 Hz, 2H), 7.53 (dt, J =
8.3 Hz, J = 1.3 Hz, 1H), 5.78 (d, J = 4.5 Hz, 1H), 5.14 (m, 1H), 
3.68–3.55 (m, 2H), 2.15–2.04 (m, 1H), 1.98–1.87 (m, 1H). 13C NMR 
(100 MHz, DMSO d6) δ 163.17, 147.36, 140.19, 133.49, 133.22, 
129.14, 128.88, 128.34, 128.22, 128.15, 123.89, 65.40, 36.02, 30.70. 
HRMS (LSIMS): m/z calcd for C16H18N3O3: 300.1348 [M + H]+; found: 
300.1343. 
4-Chloro-N-(3-hydroxy-3-(2-nitrophenyl)propyl)benzimidamide (10c). 
Orange oil; 70% yield. 1H NMR (500 MHz, CD3OD) δ 8.02 (ddd, J = 8.2 
Hz, J = 2.9 Hz, J’ = 1.2 Hz, 2H), 7.87 (d, J = 8.7 Hz, 2H), 7.82 (dt, J =
7.4 Hz, J = 1.2H, 1H), 7.71 (d, J = 8.7 Hz, 2H), 7.58 (dt, J = 7.5 Hz, J =
1.5 Hz, 1H), 5.42 (dd, J = 9.6 Hz, J = 2.4 Hz, 1H), 3.90–3.84 (m, 1H), 
3.80–3.75 (m, 1H), 2.38–2.31 (m, 1H), 2.12–2.05 (m, 1H). 13C NMR 
(125 MHz, CD3OD) δ 165.01, 148.81, 141.67, 140.74, 134.81, 130.83, 
130.80, 130.58, 129.50, 129.19, 129.23, 125.30, 67.50, 41.50, 37.29. 
HRMS (LSIMS): m/z calcd for C16H17N3O3Cl: 334.0958 [M + H]+; 
found: 334.0987. 
N-(3-Hydroxy-3-(2-nitrophenyl)propyl)-4-(trifluoromethyl)benzimida-
mide (10d). Yellow oil; 96% yield. 1H NMR (400 MHz, DMSO d6) δ 9.98 
(sa, 1H), 9.60, 9.35 (sa, 1H), 7.98 (dd, J = 26.1 z Hz, J = 8.3 Hz, 4H), 
Table 4 
ADME properties of compounds 4g, 4i, 5e, 5f and 5g.  







4g 78.52 0.29 51.65 Non Non 0.93 
4i 79.83 0.59 71.58 Non Non 0.91 
5e 79.77 0.74 3.38 Non Non − 0.16 
5f 68.28 0.20 10.40 Non Non − 0.13 
5g 81.52 0.36 55.23 Non Non 0.28 
HIA, Human Intestinal Absorption (%); BBB, Blood-Brain Barrier penetration; 
PPB, plasma protein binding; CYP3A4, Cytochrome P450 3A4; CYP2C19, Cy-
tochrome P4502C19. 
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7.91 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 7.76 (t, J = 7.5 Hz, 
1H), 7.52 (t, J = 7.5 Hz, 1H), 5.82 (sa, 1H), 5.13 (dd, J = 9.2 Hz, J = 2.1 
Hz, 1H), 3.62 (m, 2H), 2.15–2.05 (m, 1H), 1.99–1.88 (m, 2H). 13C NMR 
(100 MHz, DMSO d6) δ 162.20, 147.36, 140.19, 133.52, 133.14 (d, J =
1.0 Hz), 132.72 (q, J = 32.5 Hz), 129.40, 128.37, 128.22, 125.77 (q, J =
3.7 Hz), 123.92, 123.56 (q, J = 272.8 Hz), 65.45, 40.02, 35.94. HRMS 
(LSIMS): m/z calcd for C17H17N3O3F3: 368.1222 [M + H]+; found: 
368.1218. 
N-(3-(5-Chloro-2-nitrophenyl)-3-hydroxypropyl)acetimidamide (10e). 
Orange oil; 67% yield. 1H NMR (500 MHz, CD3OD) δ 8.00 (d, J = 8.7 Hz, 
1H), 7.91 (d, J = 2.3 Hz, 1H), 7.51 (dd, 1H, J = 8.7 Hz, J = 2.3 Hz, 1H), 
5.27 (dd, J = 9.5 Hz, J = 2.3 Hz, 1H), 3.60–3.45 (m, 2H), 2.41–2.29 (m, 
1H), 2.26 (s, 3H), 1.91–1.78 (m, 1H). 13C NMR (125 MHz, CD3OD) δ 
166.20, 146.99, 144.35, 141.08, 129.51, 129.18, 127.46, 67.24, 40.55, 
37.15, 19.04. HRMS (LSIMS): m/z calcd for C11H15N3O3Cl: 272.0796 
[M + H]+; found: 272.0789. 
N-(3-Hydroxy-3-(5-methoxy-2-nitrophenyl)propyl)acetimidamide 
(10f). Brown oil; 68% yield. 1H NMR (400 MHz, CD3OD) δ 8.08 (d, J =
9.1 Hz, 1H), 7.44 (d, J = 2.7 Hz, 1H), 7.00 (dd, J’ = 9.1 Hz, J = 2.7 Hz, 
1H), 5.42 (dd, J = 9.3 Hz, J = 2.0 Hz, 1H), 3.93 (s, 3H), 3.60–3.50 (m, 
2H), 2.28 (s, 3H), 2.21–2.08 (m, 1H), 1.90–1.76 (m, 1H). 13C NMR (100 
MHz, CD3OD) 166.14, 165.50, 145.66, 141.24, 128.65, 114.16, 113.65, 
67.68, 56.59, 40.71, 37.29, 19.07. HRMS (LSIMS): m/z calcd for 
C12H18N3O4: 268.1297 [M + H]+; found: 268.1292. 
N-(3-Hydroxy-3-(5-methoxy-2-nitrophenyl)propyl)benzimidamide 
(10g). Brown oil; 74% yield. 1H NMR (500 MHz, CD3OD) δ 8.14 (d, J =
9.1 Hz, 1H), 7.88 (d, J = 7.3 Hz, 3H), 7.78 (t, J = 7.5 Hz, 1H), 7.68 (t, J 
= 7.8 Hz, 2H), 7.53 (d, J = 2.8 Hz, 1H), 7.05 (dd, J = 9.1 Hz, J = 2.8 Hz, 
1H), 5.59 (dd, J = 9.4 Hz, J = 2.1 Hz, 1H), 3.98 (s, 3H), 3.93–3.87 (m, 
1H), 3.83–3.77 (m, 1H), 2.39––2.31 (m, 1H), 2.06–1.98 (m, 1H). 13C 
NMR (125 MHz, CD3OD) δ 165.84, 165.51, 145.67, 141.13, 134.61, 
130.57, 130.36, 128.96, 128.70, 114.21, 113.70, 67.80, 56.66, 41.43, 
37.24. HRMS (LSIMS): m/z calcd for C17H20N3O4: 330.1454 [M + H]+; 
found: 330.1449. 
4-Chloro-N-(3-hydroxy-3-(5-methoxy-2-nitrophenyl)propyl)benzimida-
mide (10h). Orange oil; 76% yield. 1H NMR (500 MHz, CD3OD) 8.14 (d, 
J = 9.1 Hz, 1H), 7.85 (d, J == 8.7 Hz, 2H), 7.68 (d, J = 8.7 Hz, 2H), 7.51 
(d, J = 2.8 Hz, 1H), 7.04 (dd, J = 9.1 Hz, J = 2.8 Hz, 1H), 5.55 (dd, J =
10.4 Hz, J = 2.1 Hz, 1H), 3.97 (s, 3H), 3.92–3.82 (m, 1H), 3.79–3.72 (m, 
1H), 2.37–2.27 (m, 1H), 2.04–1.94 (m, 1H). 13C NMR (125 MHz, 
CD3OD) δ 165.58, 165.02, 145.74, 141.21, 140.76, 130.78, 130.57, 
129.27, 128.73, 114.21, 113.71, 67.79, 56.62, 41.50, 37.22. MS 
(LSIMS): m/z calcd for C17H18N3O4Cl: 364.1059 [M + H]+; found: 
364.1051. 
N-(3-Hydroxy-3-(5-methoxy-2-nitrophenyl)propyl)-4-(trifluoromethyl) 
benzimidamide (10i). Orange oil; 68% yield. 1H NMR (500 MHz, CD3OD) 
δ 8.14 (d, J = 9.1 Hz, 1H), 8.02 (d, J = 8.3 Hz, 2H), 7.97 (d, J’ = 8.3 Hz, 
2H), 7.51 (d, J = 2.8 Hz, 1H), 7.04 (dd, J = 9.1 Hz, J = 2.8 Hz, 1H), 5.54 
(dd, J = 9.4 Hz, J = 2.1 Hz, 1H), 3.97 (s, 3H), 3.91–3.84 (m, 1H), 
3.79–3.73 (m, 1H), 2.36–2.28 (m, 1H), 2.01–1.94 (m, 1H). 13C NMR 
(125 MHz, CD3OD) δ 165.66, 165.07, 145.80, 141.29, 135.75 (q, J =
33.0 Hz), 134.56 (d, J = 1.2 Hz), 130.09, 128.78, 127.28 (q, J = 3.8 Hz), 
124.92 (q, J = 272.1 Hz), 114.20, 113.74, 67.80, 56.59, 41.60, 37.20. 
HRMS (LSIMS): m/z calcd for C18H19N3O4F3: 392.1328 [M + H]+; 
found: 398.1332. 
General method for the synthesis of N-(3-(2-nitro-5-substitutedphenyl)- 
3-oxopropyl)imidamides 11a-h. On a solution of the corresponding al-
cohols 10a-h (1.5 mmol) in acetone (15 mL) and DCM (15 mL), cooled 
to 0 ◦C, freshly prepared Jones reagent (8 mL, 2.67 M) was added 
dropwise. After 20 min, MeOH (10 mL) was added. Then, the green 
precipitate was removed by filtration. The reaction mixture was evap-
orated and was purified by flash chromatography (DCM: MeOH, 10:1 
saturating with NH4OH). 
N-(3-(2-Nitrophenyl)-3-oxopropyl)acetimidamide (11a). Orange oil; 
72% yield. 1H NMR (400 MHz, CD3OD): δ 8.16 (d, J = 8.2 Hz, 1H), 7.87 
(dd, J = 7.8 Hz, J = 7.3 Hz, 1H), 7.76 (dd, J = 8.2 Hz, J = 7.8 Hz, 1H), 
7.70 (d, J = 7.3 Hz, 1H), 3.74 (t, J = 5.9 Hz, 2H), 3.31–3.25 (m, 2H), 
2.28 (s, 3H). 13C NMR (100 MHz, CD3OD) δ 201.04, 166.23, 147.16, 
137.68, 135.62, 132.48, 128.84, 125.52, 41.14, 37.94, 19.05. HRMS 
(LSIMS): m/z calcd for: C11H14N3O3 236.1035 [M + H]+; found: 
236.1043. 
N-(3-(2-Nitrophenyl)-3-oxopropyl)benzimidamide (11b). Yellow oil; 
88% yield. 1H NMR (400 MHz, CD3OD) δ 8.22 (dd, J = 8.2 Hz, J = 0.8 
Hz, 1H), 7.91 (dt, J = 7.6 Hz, J = 3.8 Hz, 1H), 7.85–7.79 (m, 3H), 
7.79–7.73 (m, 2H), 7.71–7.63 (m, 2H), 4.03–3.95 (m, 2H), 3.50–3.32 
(m, 2H). 13C NMR (100 MHz, CD3OD) δ 201.25, 166.11, 147.24, 137.76, 
135.69, 134.63, 132.53, 130.70, 130.35, 129.02, 128.89, 125.60, 38.58, 
37.57. HRMS (LSIMS): m/z calcd for C16H16N3O3: 298.1192 [M + H]+; 
found: 298.1187. 
4-Chloro-N-(3-(2-nitrophenyl)-3-oxopropyl)benzimidamide (11c). 
White solid; mp: 177–179 ◦C; 67% yield. 1H NMR (400 MHz, CD3OD) δ 
8.20 (dd, J = 8.2 Hz, J = 0.9 Hz, 1H), 7.90 (td, J = 7.6 Hz, J = 0.9 Hz, 
1H), 7.82 (d, J = 8.6 Hz, 2H), 7.67 (d, J = 8.6 Hz, 2H), 7.42 (dd, J = 7.6 
Hz, J = 1.5 Hz, 1H), 7.31–7.27 (m, 1H), 3.96 (t, J = 5.8 Hz, 2H), 3.44 (t, 
J = 5.8 Hz, 2H). 13C NMR (100 MHz, CD3OD) δ 201.17, 165.02, 147.17, 
140.75, 137.69, 135.68, 132.50, 130.82, 130.53, 129.19, 128.91, 
125.56, 41.17, 38.72. HRMS (LSIMS): m/z calcd for C16H15N3O3Cl: 
332.0802 [M + H]+; found: 332.0791. 
N-(3-(2-nitrophenyl)-3-oxopropyl)-4-(trifluoromethyl)benzimidamide 
(11d). Orange oil; 71% yield. 1H NMR (500 MHz, CD3OD): δ 8.21 (d, J 
= 8.2 Hz, 1H), 7.98 (q, J = 8.7 Hz, 4H), 7.90 (t, J = 7.5 Hz, 1H), 7.79 (t, 
J = 7.8 Hz, 1H), 7.71 (d, J = 7.5 Hz, 1H), 3.98 (m, 2H), 3.35 (m, 2H). 13C 
NMR (125 MHz, CD3OD) δ 201.20, 165.08, 147.19, 137.74, 135.74, 
135.71(q, J = 32.9 Hz), 134.47, 132.54, 130.13, 128.89, 127.22 (q, J =
3.5 Hz), 125.61, 124.90 (q, J = 271.8 Hz), 43.92, 38.73. HRMS (LSIMS): 
m/z calcd for C17H15N3O3F3: 366.1066 [M + H]+; found: 366.1082. 
N-(3-(5-Chloro-2-nitrophenyl)-3-oxopropyl)acetimidamide (11e). Or-
ange oil; mp: 153–155 ◦C; 65% yield. 1H NMR (400 MHz, CD3OD) δ 8.23 
(d, J = 8.6 Hz, 1H), 7.79 (dd, J = 8.6 Hz, J = 2.2 Hz, 1H), 7.77 (d, J =
2.2 Hz, 1H), 3.76 (t, J = 5.8 Hz, 2H), 3.31 (t, J = 5.8 Hz, 2H), 2.31 (s, 
3H). 13C NMR (125 MHz, CD3OD) δ 198.31, 164.88, 143.97, 140.62, 
138.12, 130.85, 127.40, 126.04, 39.84, 36.36, 17.65. HRMS (LSIMS): 
m/z calcd for C11H13N3O3Cl: 270.0645 [M + H]+; found: 270.0629. 
N-(3-(5-methoxy-2-nitrophenyl)-3-oxopropyl)acetimidamide (11f). 
Yellow oil; 83% yield. 1H NMR (500 MHz, CD3OD): δ 8.22 (d, J = 9.2 Hz, 
1H), 7.20 (dd, J = 9.2 Hz, J = 2.7 Hz, 1H), 7.11 (d, J = 2.7 Hz, 1H), 3.98 
(s, 3H), 3.75 (t, J = 6.0 Hz, 2H), 3.24 (t, J = 6.0 Hz, 2H), 2.29 (s, 3H). 13C 
NMR (125 MHz, CD3OD): δ 201.20, 166.27, 166.16, 141.22, 139.28, 
128.32, 116.51, 113.57, 57.21, 41.44, 37.92, 19.06. HRMS (LSIMS): m/z 
calcd for C12H16N3O4: 266.1141 [M + H]+; found: 266.1147. 
N-(3-(5-methoxy-2-nitrophenyl)-3-oxopropyl)benzimidamide (11g). 
Brown oil; 74% yield. 1H NMR (400 MHz, CD3OD) δ 8.23 (d, J = 9.1 Hz, 
1H), 7.83 (d, J = 7.6 Hz, 2H), 7.76 (t, J = 7.3 Hz, 1H), 7.64 (t, J = 7.5 Hz, 
2H), 7.21 (dd, J’ = 9.1 Hz, J = 2.0 Hz, 1H), 7.13 (d, J = 2.0 Hz, 1H), 3.98 
(s, 3H), 3.43–3.29 (m, 4H). 13C NMR (100 MHz, CD3OD) δ 201.35, 
168.49, 166.16, 140.82, 139.18, 135.22, 128.90, 128.85, 128.62, 
128.29, 116.71, 113.52, 57.30, 45.93, 35.80. HRMS (LSIMS): m/z calcd 
for C17H18N3O4: 328.1297 [M + H]+; found: 328.1293. 
4-Chloro-N-(3-(5-methoxy-2-nitrophenyl)-3-oxopropyl)benzimidamide 
(11h). Brown oil; 76% yield. 1H NMR (400 MHz, CD3OD): δ 8.26 (d, J =
9.2 Hz, 1H), 7.82 (d, J = 8.5 Hz, 2H), 7.67 (d, J = 8.5 Hz, 2H), 7.24 (dd, 
J = 9.2, J = 2.7 Hz, 1H), 7.16 (d, J = 2.7 Hz, 1H), 4.01 (s, 3H), 3.97 (t, J 
= 5.6 Hz, 2H), 3.38–3.32 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 
201.28, 166.19, 165.15, 141.19, 140.79, 139.30, 130.83, 130.75, 
129.32, 128.36, 116.51, 113.64, 57.21, 47.94, 38.60. HRMS (LSIMS): 
m/z calcd for C17H17N3O4Cl: 362.0908 [M + H]+; found: 362.0919. 
General method for the synthesis of N-(3-(2-amino-5-substitutedphenyl)- 
3-hydroxypropyl)imidamides 4a-i and N-(3-(2-amino-5-substitutedphenyl)- 
3-oxopropyl)imidamides 5a-h. A mixture of the nitro derivatives 10a-i or 
11a-h (1 mmol) was disolved in water (10 mL), then Fe powder (10 
mmol) and FeSO4 (1 mmol) were added. The reaction was heated under 
reflux for 1.5 h. Next, the suspension was filtered through Celite. The 
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aqueous solution was evaporated under vacuum and purified by flash 
chromatography (DCM: MeOH, 8:1 saturating with NH4OH). 
N-(3-(2-Aminophenyl)-3-hydroxypropyl)acetimidamide (4a). Orange 
oil; 68% yield. 1H NMR (400 MHz, CD3OD) δ 7.14 (dd, J = 7.9 Hz, J =
1.1 Hz, 1H), 7.03 (dt, J = 7.9 Hz, J = 1.1 Hz, 1H), 6.74 (d, J = 7.9 Hz, 
1H), 6.69 (dt, J = 7.9 Hz, J = 0.8 Hz, 1H), 4.64–4.59 (m, 1H) 3.47–3.32 
(m, 2H), 2.22 (s, 3H), 2.20–2.05 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 
166.02, 146.12, 129.25, 129.12, 128.01, 119.27, 118.07, 70.82, 40.94, 
34.49, 18.99. HRMS (LSIMS): m/z calcd for C11H17N3O: 208.1450 [M +
H]+; found: 208.1435. 
N-(3-(2-Aminophenyl)-3-hydroxypropyl)benzimidamide (4b). Yellow 
oil; 71% yield. 1H NMR (500 MHz, CD3OD) δ 7.75–7.72 (m, 1H), 7.71 (d, 
J = 7.8 Hz, 2H), 7.60 (t, J = 7.8 Hz, 2H), 7.18 (d, J = 7.4 Hz, 1H), 7.05 
(td, J = 8.0, J = 1.5 Hz, 1H), 6.76 (dd, J = 8.0 Hz, J = 1.0 Hz, 1H), 6.71 
(td, J = 7.4 Hz, J = 1.0 Hz, 1H), 4.91 (dd, J = 8.4 Hz, J = 5.0 Hz, 1H), 
3.74–3.60 (m, 2H), 2.35–2.17 (m, 2H). 13C NMR (125 MHz, CD3OD) δ 
165.79, 146.19, 134.62, 130.38, 129.34, 129.14, 128.90, 128.61, 
128.07, 119.36, 118.14, 71.44, 41.79, 34.36. MS (LSIMS): m/z calcd for 
C16H19N3O: 270.1606 [M + H]+; found: 270.1597. 
N-(3-(2-Aminophenyl)-3-hydroxypropyl)-4-chlorobenzimidamide (4c). 
Yellow oil; 69% yield. 1H NMR (500 MHz, CD3OD) δ 7.70 (dt, J = 8.7 Hz, 
J = 2.1 Hz, 2H), 7.64 (dt, J = 8.7 Hz, J = 2.4 Hz, 2H), 7.18 (dd, J = 7.4 
Hz, J = 1.4 Hz, 1H), 7.06 (td, J = 7.8 Hz, J = 1.4 Hz, 1H), 6.77 (dd, J =
7.8 Hz, J = 1.1 Hz, 1H), 6.72 (td, J = 7.4 Hz, J = 1.1 Hz, 1H), 4.93–4.89 
(m, 1H), 3.61 (t, J = 7.0 Hz, 2H), 2.36–2.20 (m, 2H). 13C NMR (125 
MHz, CD3OD) δ 164.89, 146.34, 140.82, 130.69, 130.56, 129.38, 
129.24, 129.03, 128.09, 119.30, 118.11, 71.53, 41.84, 34.24. HRMS 
(LSIMS): m/z calcd for C16H19N3OCl: 304.1217 [M + H]+; found: 
304.1189. 
N-(3-(2-Aminophenyl)-3-hydroxypropyl)-4-(trifluoromethyl)benzimi-
damide (4d). Yellow oil; 65% yield. 1H NMR (500 MHz, CD3OD) δ 
7.94–7.88 (m, 4H), 7.19 (dd, J = 7.5 Hz, J = 1.5 Hz, 1H), 7.04 (td, J =
7.9 Hz, J = 1.5 Hz, 1H), 6.76 (dd, J = 7.9 Hz, J = 1.1 Hz, 1H), 6.71 (td, J 
= 7.5 Hz, J = 1.1 Hz, 1H), 4.93 (dd, J = 8.4 Hz, J = 5.2 Hz, 1H), 3.64 (t, 
J = 6.9 Hz, 2H), 2.35–2.22 (m, 2H). 13C NMR (125 MHz, CD3OD) δ 
164.70, 146.14, 135.66 (q, J = 33.4 Hz), 134.33 (d, J = 1.4 Hz), 130.07, 
129.32, 129.13, 128.08, 127.19 (q, J = 3.8 Hz), 124.88 (q, J = 271.6 
Hz), 119.36, 118.13, 71.32, 41.97, 34.29. HRMS (LSIMS): m/z calcd for 
C17H19N3OF3: 338.1480 [M + H]+; found: 338.1504. 
N-(3-(2-Amino-5-chlorophenyl)-3-hydroxypropyl)acetimidamide (4e). 
Orange oil; 67% yield. 1H NMR (400 MHz, CD3OD) δ 7.06 (d, J = 2.5 Hz, 
1H), 6.89 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 4.73 
(t, J = 7.0 Hz, 1H), 3.41–3.24 (m, 2H), 2.14 (s, 3H), 2.03–1.95 (m, 2H). 
13C NMR (100 MHz, CD3OD) δ 166.04, 145.08, 130.81, 128.75, 127.46, 
123.30, 118.90, 69.82, 40.82, 34.38, 19.03. HRMS (LSIMS): m/z calcd 
for C11H17N3OCl: 242.1060 [M + H]+; found: 242.1055. 
N-(3-(2-Amino-5-methoxyphenyl)-3-hydroxypropyl)acetimidamide 
(4f). Red oil; 68% yield. 1H NMR (400 MHz, CD3OD) δ 6.81 (d, J = 2.8 
Hz, 1H), 6.79 (d, J = 8.7 Hz, 1H), 6.70 (dd, J = 8.7 Hz, J = 2.8 Hz, 1H), 
4.96 (d, J = 3.4 Hz, 1H), 3.71 (s, 3H), 3.41–3.33 (m, 2H), 2.19 (s, 3H), 
2.12–2.04 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 166.07, 155.42, 
136.55, 132.46, 120.65, 114.80, 113.89, 70.57, 56.14, 40.83, 35.01, 
18.95. HRMS (LSIMS): m/z calcd for C12H20N3O2: 238.1556 [M + H]+; 
found: 238.1555. 
N-(3-(2-Amino-5-methoxyphenyl)-3-hydroxypropyl)benzimidamide 
(4g). Brown oil; 70% yield. 1H NMR (500 MHz, CD3OD) δ 7.77–7.72 (m, 
3H), 7.62 (t, J = 7.8 Hz, 2H), 6.88 (d, J = 2.8 Hz, 1H), 6.78 (d, J = 8.6 
Hz, 1H), 6.71 (dd, J = 8.6 Hz, J = 2.8 Hz, 1H), 4.95 (dd, J = 8.0 Hz, J =
5.3 Hz, 1H), 3.74 (s, 3H), 3.65 (t, J = 7.0 Hz, 2H), 2.30–2.23 (m, 2H). 13C 
NMR (125 MHz, CD3OD) δ 165.71, 154.55, 138.64, 134.61, 131.41, 
130.56, 130.36, 128.90, 119.78, 114.81, 113.73, 70.80, 56.13, 41.71, 
34.71. HRMS (LSIMS): m/z calcd for C17H22N3O2: 300.1712 [M + H]+; 
found: 300.1730. 
N-(3-(2-Amino-5-methoxyphenyl)-3-hydroxypropyl)-4-chlor-
obenzimidamide (4h). Brown oil; 71% yield. 1H NMR (500 MHz, CD3OD) 
δ 7.74 (d, J = 8.6 Hz, 2H), 7.65 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 2.8 Hz, 
1H), 6.77 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 8.6 Hz, J = 2.8 Hz, 1H), 4.95 
(dd, J = 7.8 Hz, J = 5.4 Hz, 1H), 3.75 (s, 3H), 3.65 (t, J = 6.9 Hz, 2H), 
2.32–2.22 (m, 2H). 13C NMR (125 MHz, CD3OD) δ 164.75, 154.44, 
140.74, 138.87, 131.27, 130.74, 130.53, 129.14, 119.67, 114.80, 
113.73, 70.74, 56.13, 41.79, 34.64. HRMS (LSIMS): m/z calcd for 
C17H21N3O2Cl: 334.1322 [M + H]+; found: 334.1313. 
N-(3-(2-Amino-5-methoxyphenyl)-3-hydroxypropyl)-4-(tri-
fluoromethyl)benzimidamide (4i). Brown oil; 75% yield. 1H NMR (500 
MHz, CD3OD) δ 7.96–7.91 (m, 4H), 6.89 (d, J’ = 2.9 Hz, 1H), 6.78 (d, J 
= 8.6 Hz, 1H), 6.72 (dd, J = 8.6 Hz, J = 2.9 Hz, 1H), 4.95 (dd, J = 8.0 Hz, 
J = 5.3 Hz, 1H), 3.75 (s, 3H), 3.67 (t, J = 6.9 Hz, 2H), 2.32–2.24 (m, 2H). 
13C NMR (125 MHz, CD3OD) δ 164.73, 154.58, 138.67, 135.70 (q, J =
33.0 Hz), 134.37, 131.40, 130.08, 127.21 (q, J = 3.7 Hz), 124.90 (q, J =
272.4 Hz), 119.79, 114.81, 113.80, 70.81, 56.13, 41.89, 34.61 (C-2′). 
HRMS (LSIMS): m/z calcd for C18H21N3O2F3: 368.1586 [M + H]+; 
found: 368.1573. 
N-(3-(2-Aminophenyl)-3-oxopropyl)acetimidamide (5a). Orange solid; 
mp: 130–133 ◦C; 88% yield. 1H NMR (500 MHz, CD3OD): δ 7.79 (dd, J =
8.2 Hz, J = 1.5 Hz, 1H), 7.30 (ddd, J = 8.4 Hz, J = 6.9 Hz, J = 1.5 Hz, 
1H), 6.80 (dd, J = 8.4 Hz, J = 1.2 Hz, 1H), 6.65 (ddd, J = 8.2 Hz, J = 6.9 
Hz, J = 1.2 Hz, 1H), 3.67 (t, J = 6.1 Hz, 2H), 3.40 (t, J = 6.1 Hz, 2H), 
2.24 (s, 3H). 13C NMR (125 MHz, CD3OD) δ 199.90, 166.03, 152.81, 
135.75, 131.97, 118.42, 118.05, 116.27, 38.72, 37.40, 18.87. HRMS 
(LSIMS): m/z calcd for C11H14N3O3: 206.1293 [M + H]+; found: 
206.1291. 
N-(3-(2-Aminophenyl)-3-oxopropyl)benzimidamide (5b). Yellow oil; 
69% yield. 1H NMR (400 MHz, CD3OD): δ 7.72 (dd, J = 8.2 Hz, J = 1.3 
Hz, 1H), 7.65–7.60 (m, 2H), 7.59–7.56 (m, 1H), 7.48 (dd, J = 10.8 Hz, J 
= 4.4 Hz, 2H), 7.18 (ddd, J = 8.4 Hz, J = 7.0 Hz, J = 1.3 Hz, 1H), 6.70 
(dd, J = 8.4 Hz, J = 1.1 Hz, 1H), 6.54 (ddd, J = 8.2 Hz, J = 7.0 Hz, J =
1.1 Hz, 1H), 3.76 –3.69 (m, 2H), 3.31–3.25 (m, 2H). 13C NMR (100, 
CD3OD) δ 200.56, 165.62, 152.67, 135.62, 133.99, 132.10, 131.87, 
130.18, 128.71, 118.38, 117.59, 116.30, 43.45, 39.72. HRMS (LSIMS): 
m/z calcd for C16H18N3O: 268.1450 [M + H]+; found: 268.1440. 
N-(3-(2-Aminophenyl)-3-oxopropyl)-4-chlorobenzimidamide (5c). 
Brown oil; 75% yield. 1H NMR (600 MHz, CD3OD) δ 7.73 (d, J = 5.8 Hz, 
1H), 7.54 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 7.18 (t, J = 8.0 
Hz, 1H), 6.69 (d, J = 8.0 Hz, 1H), 6.54 (t, J = 8.0 Hz, 1H), 3.47 (t, J =
7.5 Hz, 2H), 2.91 (t, J = 7.5 Hz, 2H). 13C NMR (150 MHz, CD3OD) δ 
202.69, 165.03, 152.54, 137.20, 136.76, 134.25, 132.23, 129.60, 
129.56, 127.31, 118.04, 115.56, 40.53, 34.90. HRMS (LSIMS): m/z 
calcd for C16H17N3OCl: 302.1060 [M + H]+; found: 302.1036. 
N-(3-(2-Aminophenyl)-3-oxopropyl)-4-(trifluoromethyl)benzimidamide 
(5d). Orange oil; 78% yield. 1H NMR (400 MHz, CD3OD): δ 8.22 (d, J =
7.6 Hz, 1H), 7.99 (q, J = 8.8 Hz, 4H), 7.91 (t, J = 7.6 Hz, 1H), 7.80 (t, J 
= 7.6 Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H), 4.03–3.94 (m, 2H), 3.36–3.33 
(m, 2H). 13C NMR (100 MHz, CD3OD) δ 201.18, 165.16, 147.24, 137.81, 
135.78 (q, J = 33.2 Hz), 135.76, 134.53, 132.57, 130.13, 128.84, 
127.23 (q, J = 3.5 Hz), 125.66, 124.92 (q, J = 271.7 Hz), 38.68, 37.78. 
HRMS (LSIMS): m/z calcd for C17H17N3OF3: 336.1324 [M + H]+; found: 
336.1308. 
N-(3-(2-Amino-5-chlorophenyl)-3-oxopropyl)acetimidamide (5e). Or-
ange oil; 78% yield. 1H NMR (500 MHz, CD3OD): δ 7.73 (d, J = 2.4 Hz, 
1H), 7.21 (dd, J = 8.9 Hz, J = 2.4 Hz, 1H), 6.79 (d, J = 8.9 Hz, 1H), 3.64 
(t, J = 6.1 Hz, 2H), 3.35 (t, J = 6.1 Hz, 2H), 2.22 (s, 3H). 13C NMR (125 
MHz, CD3OD) δ 199.04, 166.01, 151.38, 135.53, 130.86, 120.16, 
120.09, 118.36, 38.59, 37.46, 18.95. HRMS (LSIMS): m/z calcd for 
C11H15N3OCl: 240.0904 [M + H]+; found: 240.0886. 
N-(3-(2-Amino-5-methoxyphenyl)-3-oxopropyl)acetimidamide (5f). 
Brown oil; 69% yield. 1H NMR (400 MHz, CD3OD) δ 7.23 (d, J = 2.8 Hz, 
1H), 7.01 (dd, J = 9.0 Hz, J = 2.8 Hz, 1H), 6.78 (d, J = 9.0 Hz, 1H), 3.78 
(s, 3H), 3.66 (t, J = 6.1 Hz, 2H), 3.39 (t, J = 6.1 Hz, 2H), 2.23 (s, 3H). 13C 
NMR (125 MHz, CD3OD) δ 199.50, 166.01, 151.24, 147.48, 125.13, 
120.01, 117.82, 113.87, 56.45, 38.73, 37.58, 18.90. HRMS (LSIMS): m/z 
calcd for C12H18N3O2: 236.1399 [M + H]+; found: 236.1388. 
N-(3-(2-Amino-5-methoxyphenyl)-3-oxopropyl)benzimidamide (5g). 
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Orange oil; 84% yield. 1H NMR (400 MHz, CD3OD): δ 7.80–7.74 (m, 
3H), 7.64 (dd, J = 10.9 Hz, J = 4.5 Hz, 2H), 7.30 (d, J = 2.9 Hz, 1H), 
7.05 (dd, J = 9.0 Hz, J = 2.9 Hz, 1H), 6.81 (d, J = 9.0 Hz, 1H), 3.91 (t, J 
= 6.2 Hz, 2H), 3.82 (s, 3H), 3.55 (t, J = 6.2 Hz, 2H). 13C NMR (125 MHz, 
CD3OD) δ 199.81, 165.88, 151.27, 147.48, 134.60, 130.62, 130.34, 
128.94, 125.20, 120.05, 117.91, 113.94, 56.51, 39.74, 37.66. HRMS 
(LSIMS): m/z calcd for C17H20N3O2: 298.1556 [M + H]+; found: 
298.1553. 
N-(3-(2-Amino-5-methoxyphenyl)-3-oxopropyl)-4-chlor-
obenzimidamide (5h). Yellow oil; 83% yield. 1H NMR (400 MHz, 
CD3OD): δ 7.76 (d, J = 8.5 Hz, 2H), 7.66 (d, J = 8.5 Hz, 2H), 7.29 (d, J =
2.7 Hz, 1H), 7.08 (dd, J = 9.0 Hz, J = 2.7 Hz, 1H), 6.85 (d, J = 9.0 Hz, 
1H), 3.89 (t, J = 6.0 Hz, 2H), 3.81 (s, 3H), 3.35 (t, J = 6.0 Hz, 2H). 13C 
NMR (100 MHz, CD3OD) δ 199.73, 164.97, 151.28, 147.51, 140.77, 
130.76, 130.65, 130.55, 125.22, 120.04, 117.89, 113.96, 56.50, 47.94, 
39.70. HRMS (LSIMS): m/z calcd for C17H19N3O2Cl: 332.1166 [M +
H]+; found: 332.1179. 
4.2. In vitro nNOS and iNOS activity determination 
Enzymatic inhibition determination of the final products was carried 
out following different procedures depending on each isoform of NOS. 
Most of the used compounds were supplied by Sigma-Aldrich (Merk), 
except the tritium-labeled L-[3H]-arginine, from Amersham Biosciences 
(Perkin Elmer) and the human enzymes iNOS and nNOS recombinants, 
from Enzo Life Sciences (Taper). 
In these two isoforms, the in vitro enzymatic activity tests were 
performed in triplicate, following the Bredt & Snyder methodology.40 
The basic foundation of this methodology is the control of the con-
version of L-[3H]-arginine to L-[3H]-citrulline, due to the use of a 
Beckman LS 6500 multi-purpouse scintillation counter detector. 
The final volume for each one of the replicates is 100 μl, of which: 50 
µl correspond to a buffer solution containing 25 mM tris-(hydrox-
ymethyl)-aminomethane hydrochloride (Tris-HCl), 1 mM DL-dithio-
threitol (DTT), 4 µM 5,6,7,8-tetrahydro-L-biopterin dihydrochloride 
(BH4), 10 µM flavin-adenine dinucleotide (FAD), 0.5 mM hypoxanthine- 
9-ribofuranoside (inosine), 0.5 mg/ml bovine serum albumin (BSA), 0.1 
mM CaCl2, 10 µM L-arginine, 10 µg/ml calmodulin (CaM) (only in 
nNOS) and 0.05 µM L-[3H]-arginine, always maintaining a pH of 7.6; 10 
µl of an aliquot of the NOS isoform correspondent to the study per-
formed; 10 µl of a solution of the product to be evaluated; 10 µl of 7.5 
mM NADPH (except in control wells); and, finally, enough H2O MiliQ to 
reach 100 µl. 
All samples are incubated for 30 min at 37 ◦C. After that, 400 µl of a 
low-temperature buffer is added to stop the enzymatic process. This 
solution contains 0.1 M N-(2-hydroxymethyl)piperazine-N’-(2-ethane-
sulfonic) (HEPES) acid, 10 mM ethylene glycol-bis-(2-aminoethyl 
ether)-N,N,N’,N’-tetraacetic acid (EGTA) and 0.175 mg/ml L-citrulline 
at pH = 5.5. 
The sudden drop in temperature, the pH change and the dilution of 
all the components found in the reaction well, are the main factors that 
cause the stop of the enzymatic reaction; in addition, EGTA is also 
capable of chelating the Ca2+ ions, essential for the dimerization and 
functioning of the enzyme. 
After this stage, each sample is passed through a column with 
Dowex-50 W ion exchange resin (Na+) and then washed with H2O MiliQ 
(1.2 mL), thus losing about 98% of the radioactivity. 
Finally, 50 µl of each replica are diluted in Eco Lite (+) scintillation 
liquid to take measurements the next day, once other factors capable of 
exciting the scintillation liquid beyond the β emissions are eliminated. 
NOS activity is expressed in picomoles of L-citrulline produced per 
mg of protein per minute (pM/mg min). 
For the statistical treatment of data, the Prism8 program of GraphPad 
was used, where the IC50 calculation was carried out by means of non- 
linear regression ELISA studies with variable slope of four factors. 
4.3. In vitro eNOS activity determination 
In order to evaluate the eNOS activity, it has been necessary working 
with tissue from experimental animals. Regulations for the protection of 
animals used for scientific purposes of the European Union were fol-
lowed to carry out this study. All experimental protocols were approved 
by the Animal Care and Ethics Committee of the University of Granada 
(Spain; permit no: 12/11/2017/164). Male Wistar rats (250–300 g), 
obtained from Harlam Laboratories SA (Barcelona, Spain), were eutha-
nized by a quick blow on the head followed by exsanguination. 
The descending thoracic aortic rings were dissected. Then, they were 
mounted in organ chambers filled with Krebs solution (composition in 
mM: NaCl, 118; KCl, 4.75; NaHCO3, 25; MgSO4, 1.2; CaCl2, 2; KH2PO4, 
1.2; and glucose, 11) at 37 ◦C and gassed with 95% O2 and 5% CO2 and 
were stretched to 2 g of resting tension by means of two L-shaped 
stainless-steel wires inserted into the lumen and attached to the chamber 
and to an isometric force–displacement transducer (UF-1, Cibertec, 
Madrid, Spain), and recorded in a recording and analysis system 
(MacLab ADInstruments), as described previously.39 
Rings were then mounted in organ chambers filled with Krebs so-
lution and were stretched to 2 g of resting tension by means of two L- 
shaped stainless-steel wires inserted into the lumen and attached to the 
chamber and to an isometric force–displacement transducer (UF-1, 
Cibertec, Madrid, Spain), and recorded in a recording and analysis sys-
tem (MacLab ADInstruments), as described previously.41 
After stabilization of the medium conditions, these rings were incu-
bated with a known eNOS inhibitor: L-NAME (100 μM), the compound 4i 
(20 μM), or its vehicle (DMSO, 1/106) for 30 min. The contraction was 
then induced by a [1 µM] norepinephrine solution. Once a plateau 
contraction was reached, a concentration–response curve was con-
structed by cumulative addition of acetylcholine. Results are expressed 
as percentage of norepinephrine-evoked contraction. Data are expressed 
as means ± standard error mean and n reflects the number of aortic rings 
from different rats. Statistically significant differences among groups 
were calculated by two-way ANOVA followed by a Dunnett’s multiple 
comparison test. P < 0.05 was considered statistically significant. 
4.4. Cell viability assay 
To examine the cytotoxicity induced by compounds 4g, 4i, 5e and 5f, 
changes in the viability of HUVECs, after incubation with these com-
pounds, were evaluated by assessing mitochondrial activity by the MTT 
reduction assay. Briefly, HUVECs were seeded at 1x104 cells per well in a 
96-well microtiter plate and incubated at 37 ◦C for up to 24 h. Then, the 
cells supernatants were removed and replaced by fresh medium serum 
free for at least two hours before the cells were exposed to serial di-
lutions of compounds (10 - 500 µM) for 30 min. At the selected time, 20 
uL of 5 mg/ml MTT in PBS was added to the cells and further incubated 
at 37 ◦C for 3 h. After washing, 100 µl of DMSO were added into each 
well, and the spectrophotometric analysis was run at 570 nm using a 
multi-well plate reader (Fluorostart; BMG Labtechnologies, Offenburg, 
Germany) with background subtraction at 630 nm. Cell viability was 
calculated as the percentage of the viable cells compared with untreated 
controls. The viability experiments were conducted in at least three in-
dependent times, each run in triplicate. Results are expressed as per-
centage relatively to the untreated condition. 
4.5. Docking studies 
4.5.1. Docking protocol 
Docking studies were carried out with Autodock 4.2.6 (AD4)42 on the 
iNOS and nNOS pdb IDs 4CX7 and 6AV2, respectively. Ligands struc-
tures were built on Avogadro43 and optimized using Gaussian44 (HF/6- 
31G(d,p)). Compounds presenting tertiary amines, prone to protonation 
at physiological pH, were also considered. Once optimized, ligands PDBs 
were prepared for docking using the prepare_ligand4.py script included 
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MGLTools 1.5.4.42 Protein structures, on the other hand, were prepared 
for docking using the PDB2PQR tools.45 Water and ligand molecules 
were removed and charges and non-polar hydrogen atoms were added at 
pH 7.0. The produced structures were saved as a pdb files and prepared 
for docking using the prepare_receptor4.py script from MGLTools. The 
Fe atom of heme was assigned a charge of +3. AD4 was used to auto-
matically dock the ligands into the iNOS and nNOS binding sites. For 
both enzymes, the docking grid was centered on the ligand binding site 
and set with the following grid parameters: 60 Å × 60 Å × 60 Å with 
0.375 Å spacing. In all calculations, AD4 parameter file was set to 100 
GA runs, 2.500.000 energy evaluations and a population size of 150. The 
Lamarckian genetic algorithm local search (GALS) method was used for 
the docking calculations. All dockings were performed with a population 
size of 250 and a Solis and Wets local search of 300 rounds was applied 
with a probability of 0.06. A mutation rate of 0.02 and a crossover rate of 
0.8 were used. The docking results from each of the 100 calculations 
were clustered based on root-mean square deviation (RMSD) solutions 
differing by less than 2.0 Å between the Cartesian coordinates of the 
atoms and ranked on the basis of free energy of binding. 
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